Información del artículo
Resumen
Aunque el campo de los trastornos del movimiento incluye en su mayoría patologías subagudas o crónicas atendidas habitualmente en consultas externas, en ocasiones se presentan cuadros agudos cuyo reconocimiento y tratamiento urgentes son imperativos. En este artículo se revisan aquellas entidades que con frecuencia requieren un manejo neurointensivista y cuya evolución puede resultar “catastrófica”. Entre ellas se incluyen el síndrome neuroléptico maligno y otros cuadros relacionados, el estado distónico y el hemibalismo.
Palabras clave:
Estado distónico
Hemibalismo
Síndrome neuroléptico maligno
Trastornos del movimiento
Urgencias
Abstract
The field of movement disorders largely covers subacute or chronic diseases that are usually treated in outpatient clinics. However, the much less frequent acute disorders require urgent recognition and treatment. The present article reviews the entities that frequently require neurointensive management and whose development can prove “calamitous”. These include neuroleptic malignant syndrome and related conditions, status dystonicus, and hemiballism.
Keywords:
Status dystonicus
Hemiballism
Neuroleptic malignant syndrome
Movement disorders
Emergencies
El Texto completo está disponible en PDF
Bibliografía
[1.]
S.N. Caroff, S.C. Mann.
Neuroleptic malignant syndrome.
Med Clin North Am., 77 (1993), pp. 185-202
[2.]
J.R. Strawn, P.E. Keck Jr., S.N. Caroff.
Neuroleptic malignant syndrome.
Am J Psychiatry., 164 (2007), pp. 870-876
[3.]
I. Kishida, C. Kawanishi, T. Furuno, T. Matsumura, H. Hasegawa, N. Sugiyama, et al.
Lack of association in Japanese patients between neuroleptic malignant syndrome and the TaqI A polymorphism of the dopamine D2 receptor gene.
Psychiatr Genet., 13 (2003), pp. 55-57
[4.]
D. Kato, C. Kawanishi, I. Kishida, T. Furuno, K. Suzuki, H. Onishi, et al.
Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.
Eur J Clin Pharmacol., 63 (2007), pp. 991-996
[5.]
D. Berardi, M. Amore, P.E. Keck Jr., M. Troia, M. Dell’Atti.
Clinical and pharmacologic risk factors for neuroleptic malignant syndrome: a case-control study.
Biol Psychiatry., 44 (1998), pp. 748-754
[6.]
S.C. Hu, S.J. Frucht.
Emergency treatment of movement disorders.
Curr Treat Options Neurol., 9 (2007), pp. 103-114
[7.]
E.J. Newman, D.G. Grosset, P.G. Kennedy.
The parkinsonism-hyperpyrexia syndrome.
Neurocrit Care., 10 (2009), pp. 136-140
[8.]
S. Kuno, E. Mizuta, S. Yamasaki.
Neuroleptic malignant syndrome in parkinsonian patients: risk factors.
Eur Neurol., 38 (1997), pp. S56-S59
[9.]
Y. Sato, T. Asoh, N. Metoki, K. Satoh.
Efficacy of methylprednisolone pulse therapy on neuroleptic malignant syndrome in Parkinson's disease.
J Neurol Neurosurg Psychiatry., 74 (2003), pp. 574-576
[10.]
S.C. Mann, S.N. Caroff, H.R. Bleier, W.K. Welz, M.A. Kling, M. Hayashida.
Lethal catatonia.
Am J Psychiatry., 143 (1986), pp. 1374-1381
[11.]
G. Northoff.
Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology.
J Neural Transm., 109 (2002), pp. 1453-1467
[12.]
S.N. Caroff, S.C. Mann, P.E. Keck Jr., A. Francis.
Residual catatonic state following neuroleptic malignant syndrome.
J Clin Psychopharmacol., 20 (2000), pp. 257-259
[13.]
J.A. Blackman, P.D. Patrick, M.L. Buck, R.S. Rust Jr..
Paroxysmal autonomic instability with dystonia after brain injury.
Arch Neurol., 61 (2004), pp. 321-328
[14.]
C. Sun-Edelstein, S.J. Tepper, R.E. Shapiro.
Drug-induced serotonin syndrome: a review.
Expert Opin Drug Saf., 7 (2008), pp. 587-596
[15.]
W.W. McDaniel.
Serotonin syndrome: early management with cyproheptadine.
Ann Pharmacother., 35 (2001), pp. 870-873
[16.]
L.W. Kao, Y. Amin, M.A. Kirk, M.S. Turner.
Intrathecal baclofen withdrawal mimicking sepsis.
J Emerg Med., 24 (2003), pp. 423-427
[17.]
J.M. Meythaler, J.F. Roper, R.C. Brunner.
Cyproheptadine for intrathecal baclofen withdrawal.
Arch Phys Med Rehabil., 84 (2003), pp. 638-642
[18.]
H. Manji, R.S. Howard, D.H. Miller, N.P. Hirsch, L. Carr, K. Bhatia, et al.
Status dystonicus: the syndrome and its management.
Brain., 121 (1998), pp. 243-252
[19.]
P. Mariotti, A. Fasano, M.F. Contarino, G. Della Marca, M. Piastra, O. Genovese, et al.
Management of status dystonicus: our experience and review of the literature.
Mov Disord., 22 (2007), pp. 963-968
[20.]
A. Dalvi, S. Fahn, B. Ford.
Intrathecal baclofen in the treatment of dystonic storm.
Mov Disord., 13 (1998), pp. 611-612
[21.]
F. Escamilla Sevilla, M.J. Pérez-Navarro, M.J. Katati, J.M. Martín Linares, F. Sánchez Caballero, P. Del Saz Saucedo, et al.
Tratamiento del estado distónico mediante estimulación cerebral profunda del globo pálido interno bilateral.
Rev Neurol., 44 (2007), pp. 564-565
[22.]
Ministerio de Sanidad y Política Social. “Estadísticas Sanitarias: enfermedades de declaración obligatoria” [en línea]. [Consulta: 18 mayo 2009]. Disponible en: http://www.msps.es/estadEstudios/estadisticas/estadisticas/estMinisterio/declarObligatoria
[23.]
I.H. Mallick, M.C. Winslet.
A review of the epidemiology, pathogenesis and management of tetanus.
Int J Surg., 2 (2004), pp. 109-112
[24.]
C.L. Thwaites, L.M. Yen, H.T. Loan, T.T. Thuy, G.E. Thwaites, K. Stepniewska, et al.
Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial.
Lancet., 368 (2006), pp. 1436-1443
[25.]
M. Solsona, G. Miró, J.C. Yebenes, X. Balanzo, J. Almirall, M. Mauri.
Tétanos tratado con perfusión continua de baclofen intratecal.
Med Intensiva., 31 (2007), pp. 204-206
[26.]
M.E. Duddy, M.R. Baker.
Stiff person syndrome.
Front Neurol Neurosci., 26 (2009), pp. 147-165
[27.]
A.N. Poncelet.
Blink reflexes and the silent period in tetanus.
Muscle Nerve., 23 (2000), pp. 1435-1438
[28.]
C. Stayer, V. Tronnier, J. Dressnandt, E. Mauch, G. Marquardt, K. Rieke, et al.
Intrathecal baclofen therapy for stiff-man syndrome and progressive encephalomyelopathy with rigidity and myoclonus.
Neurology., 49 (1997), pp. 1591-1597
[29.]
A. Saiz, A. Mínguez, F. Graus, C. Marín, E. Tolosa, F. Cruz-Sánchez.
Stiff-man syndrome with vacuolar degeneration of anterior horn motor neurons.
J Neurol., 246 (1999), pp. 858-860
[30.]
K.L. Poston, S.J. Frucht.
Movement disorder emergencies.
J Neurol., 255 (2008), pp. S2-S13
[32.]
J.H. Wang, T. Wu, B.Q. Deng, Y.W. Zhang, P. Zhang, Z.K. Wang.
Hemichorea-hemiballismus associated with nonketotic hyperglycemia: A possible role of inflammation.
J Neurol Sci., 284 (2009), pp. 198-202
[33.]
T. Tsubokawa, Y. Katayama, T. Yamamoto.
Control of persistent hemiballismus by chronic thalamic stimulation. Report of two cases.
J Neurosurg., 82 (1995), pp. 501-505
[34.]
K.V. Slavin, T.K. Baumann, K.J. Burchiel.
Treatment of hemiballismus with stereotactic pallidotomy. Case report and review of the literature.
Neurosurg Focus., 17 (2004), pp. E7
[35.]
H. Hasegawa, N. Mundil, M. Samuel, J. Jarosz, K. Ashkan.
The treatment of persistent vascular hemidystonia-hemiballismus with unilateral GPi deep brain stimulation.
Mov Disord., 24 (2009), pp. 1697-1698
Copyright © 2010. Sociedad Española de Neurología
